In vitro and in vivo activities of LCB01-0371, a new oxazolidinone

  • Antimicrob Agents Chemother. 2010 Dec;54(12):5359-62. doi: 10.1128/AAC.00723-10.
Ji-Woong Jeong  1 ,  Sung-Ji Jung ,  Hyun-Hee Lee ,  Yong-Zu Kim ,  Tae-Kyo Park ,  Young-Lag Cho ,  Sang-Eun Chae ,  Sung-Yoon Baek ,  Sung-Ho Woo ,  Hyang-Sook Lee ,  Jin-Hwan Kwak
Affiliations
  • 1. School of Life Science, Handong Global University, Puk-ku, Pohang City, Kyungbuk 791-708, Republic of Korea.
PMID: 20855730 DOI: 10.1128/AAC.00723-10
Abstract

LCB01-0371 is a new Oxazolidinone with cyclic amidrazone. In vitro activity of LCB01-0371 against 624 clinical isolates was evaluated and compared with those of linezolid, vancomycin, and Other Antibiotics. LCB01-0371 showed good activity against Gram-positive pathogens. In vivo activity of LCB01-0371 against systemic infections in mice was also evaluated. LCB01-0371 was more active than linezolid against these systemic infections. LCB01-0371 showed bacteriostatic activity against Staphylococcus aureus.

Products